The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Abstract

China is one of the countries with the highest incidence of gastric cancer. There are differences in epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selection between gastric cancer patients from the Eastern and Western countries. Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients. The Chinese Society of Clinical Oncology (CSCO) arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile, discuss, and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad. By referring to the opinions of industry experts, taking into account of regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted experts’ consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes. This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis, comprehensive treatment, and follow-up visits for gastric cancer.

Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer

“…All patients had undergone adjuvant chemotherapy with capecitabine plus oxaliplatin (XELOX). The median number of chemotherapy cycles was 6 (range, [3][4][5][6][7][8][9][10][11][12]. Overall survival (OS) was defined as the time from surgery to death or the last follow-up.…”

Deregulation of CSMD1 targeted by microRNA-10b drives gastric cancer progression through the NF-κB pathway

“…Despite a steadily declining incidence, it newly occurred in 950,000 Ivyspring International Publisher people and caused 723,000 deaths in 2012 [1]. In the past few decades, although the diagnosis and treatment of gastric cancer has indeed improved significantly, the 5-year survival rate of patients with advanced gastric cancer, especially metastatic gastric cancer, is still very low [3]. Hunman CUB and sushi multiple domains protein 1 (CSMD1) is a novel candidate tumor suppressor gene located on the p arm of chromosome 8 (8p23) [4].…”

PD‑L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer

“…Multivariate logistic regression analysis. regimen (33). Since there were fewer patients in the single-agent and three-drug combination chemotherapy groups, the patients with double-drug combination chemotherapy were further analyzed.…”